Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N
Signal Transduct Target Ther. 2025; 10(1):11.
PMID: 39800748
PMC: 11734941.
DOI: 10.1038/s41392-024-02080-z.
Wang J, Yang J, Narang A, He J, Wolfgang C, Li K
J Hematol Oncol. 2024; 17(1):92.
PMID: 39390609
PMC: 11468220.
DOI: 10.1186/s13045-024-01613-x.
Long S, Amparo A, Goodhart G, Ahmad S, Waters A
Front Oncol. 2024; 14:1402128.
PMID: 38800401
PMC: 11116577.
DOI: 10.3389/fonc.2024.1402128.
Randelovic I, Nyiri K, Koppany G, Baranyi M, Tovari J, Kigyos A
Int J Mol Sci. 2024; 25(5).
PMID: 38473821
PMC: 10932042.
DOI: 10.3390/ijms25052572.
Gao Y, Packeiser E, Wendt S, Sekora A, Cavalleri J, Pratscher B
Genes (Basel). 2024; 15(2).
PMID: 38397192
PMC: 10887541.
DOI: 10.3390/genes15020202.
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in -mutant cancers.
Jansen R, Mainardi S, Dias M, Bosma A, van Dijk E, Selig R
Proc Natl Acad Sci U S A. 2024; 121(9):e2319492121.
PMID: 38377196
PMC: 10907260.
DOI: 10.1073/pnas.2319492121.
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C, Delle Cave D, Papavassiliou A
Int J Mol Sci. 2024; 25(3).
PMID: 38338909
PMC: 10855714.
DOI: 10.3390/ijms25031631.
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette G, Bear A, Carreno B
Clin Cancer Res. 2024; 30(10):2017-2024.
PMID: 38266167
PMC: 11094419.
DOI: 10.1158/1078-0432.CCR-23-1212.
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J, Timar J
Pathol Oncol Res. 2024; 29:1611580.
PMID: 38239281
PMC: 10794394.
DOI: 10.3389/pore.2023.1611580.
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
Kim J
Int J Mol Sci. 2023; 24(23).
PMID: 38069255
PMC: 10707712.
DOI: 10.3390/ijms242316933.
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure.
de Jesus V, Mathias-Machado M, de Farias J, Aruquipa M, Jacome A, Peixoto R
Cancers (Basel). 2023; 15(20).
PMID: 37894382
PMC: 10605759.
DOI: 10.3390/cancers15205015.
Synchronous primary colorectal mucinous adenocarcinoma and pancreatic ductal adenocarcinoma: A case report.
Qiu X, Ni B, Shen Y, Zhang Y, Xia X, Cao H
Oncol Lett. 2023; 26(3):405.
PMID: 37600331
PMC: 10436161.
DOI: 10.3892/ol.2023.13991.
Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
Zhou X, Ji Y, Zhou J
Molecules. 2023; 28(8).
PMID: 37110848
PMC: 10146153.
DOI: 10.3390/molecules28083615.
